Compare SEZL & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SEZL | APGE |
|---|---|---|
| Founded | 2016 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | 2023 | 2023 |
| Metric | SEZL | APGE |
|---|---|---|
| Price | $153.89 | $134.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $109.33 | ★ $109.67 |
| AVG Volume (30 Days) | 600.7K | ★ 2.0M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $450,279,000.00 | N/A |
| Revenue This Year | $30.30 | N/A |
| Revenue Next Year | $24.79 | N/A |
| P/E Ratio | $108.17 | ★ N/A |
| Revenue Growth | ★ 66.08 | N/A |
| 52 Week Low | $49.50 | $34.34 |
| 52 Week High | $195.71 | $134.40 |
| Indicator | SEZL | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 80.56 |
| Support Level | $60.73 | $80.52 |
| Resistance Level | $190.36 | N/A |
| Average True Range (ATR) | 12.49 | 0.36 |
| MACD | -4.44 | -1.74 |
| Stochastic Oscillator | 1.30 | 90.57 |
Sezzle Inc is a financing institution that offers technology-driven payment platform. The Sezzle Platform offers a payments solution for consumers in the United States and Canada that has the ability to instantly extend credit at the point-of-sale, allowing consumers to purchase and receive merchandise while paying in installments over time. Consumers pay a portion of the purchase price at the point-of-sale as a down payment, and then pay off the remaining amount over time through scheduled payments. It also offer the ability to pay-in-full using the Sezzle Platform. Its operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.